Plain-English translation of NCT06937528 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing whether —tiny particles naturally released by cells—can help treat severe knee arthritis when injected directly into the knee joint. Researchers will give 50 patients with advanced knee arthritis two doses of these cell particles and then carefully monitor how well they work using physical exams, blood tests, and MRI imaging.
Severe knee arthritis causes pain, stiffness, and disability for many people, and current treatments don't work well for everyone. This medication offers a new approach using the body's own cellular messengers to potentially reduce inflammation and help the knee heal.
You likely qualify if…
You likely don't qualify if…
You will receive two injections of the cell particles directly into your knee joint. After each injection, you'll have follow-up visits where doctors will examine your knee, take blood samples, and perform MRI scans to see how the treatment is working and monitor for any side effects.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Jordan
Sponsor
University of Jordan
Collaborators
Abdalla Awidi Abbadi, MD
Enrollment target
~50 participants
Started
January 2024
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
42 Years – 75 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hanan Jafar, PhD
University of Jordan
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.